| Author(s) | |
|---|---|
| Abstract |
With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections. |
| Format | |
| Identifier(s) | |
| Publication Date |
2020-04-14
|
| Publication Title |
The Journal of experimental medicine
|
| Publisher | |
| Volume |
217
|
| Issue |
5
|
| Keywords | |
| License |
Creative Commons Attribution-Noncommercial-Share Alike 4.0
|
| Community | |
| Recommended Citation |
Piontkivska, Helen; Ludmila Prokunina-Olsson; Noémie Alphonse; Ruth E. Dickenson; Joan E. Durbin; Jeffrey S. Glenn; Rune Hartmann; Sergei V. Kotenko; Helen M. Lazear; Thomas R. O’Brien; Charlotte Odendall; Olusegun O. Onabajo; Deanna M. Santer; Nancy C. Reich; Andreas Wack; Ivan Zanoni (2020). COVID-19 and emerging viral infections: The case for interferon lambda. The Journal of experimental medicine 217(5) doi: https://doi.org/10.1084/jem.20200653. Retrieved from https://oaks.kent.edu/covid19ksu/covid-19-and-emerging-viral-infections-case-interferon-lambda
|